Here are 1-3 brief analogies to describe Tenon Medical (TNON):

• Like Stryker or Zimmer Biomet, but entirely focused on instruments and implants for sacroiliac joint fusion surgery.
• A specialized medical device company, akin to Globus Medical, but exclusively dedicated to sacroiliac joint fixation systems.

• The CATAMARAN SIJ Fusion System: A surgical implant system comprising instruments and implants designed to prepare and fixate the sacroiliac (SI) joint for fusion surgery.

Tenon Medical, Inc. (TNON) primarily sells its surgical implant systems and related instruments to healthcare institutions. Its major customers fall into the following categories:

• Hospitals: These are large medical facilities with surgical departments that perform sacroiliac joint fixation/fusion surgeries and purchase medical devices like the CATAMARAN SIJ Fusion System.
• Ambulatory Surgical Centers (ASCs): These are outpatient facilities that specialize in various surgical procedures, including spine and orthopedic surgeries, and represent a significant market for medical device companies.

Steven M. Foster Chief Executive Officer & President

Mr. Foster has served as Chief Executive Officer & President of Tenon Medical since June 2021. He brings over 30 years of experience in marketing, sales, operations, and general management within the medical device industry. Prior to Tenon Medical, Mr. Foster was a principal with CTB Advisors, LLC, where he provided consultative assistance on commercialization-focused projects for medical device organizations, including clients such as NuVasive, SafeOp Surgical, and Alphatec Spine. His experience also includes serving as President, North America at Safe Orthopaedics, and holding various leadership roles at Medtronic Spine and Biologics, including Vice President of Sales - Biologics. He also held supervisory roles at Stryker.

Kevin Williamson Chief Financial Officer

Mr. Williamson was appointed Chief Financial Officer of Tenon Medical, effective September 3, 2024. He most recently served as the Chief Financial Officer at Accelus Inc., a medical device company specializing in expandable spinal implant technology, where he oversaw finance, investor relations, and IT functions. From 2019 to 2020, he was the Director of Finance at Accelus Inc. Additionally, from 2015 to 2019, Mr. Williamson held various roles in the Corporate Finance department at NuVasive, Inc., a medical device company focused on minimally invasive spine surgery.

Richard Ferrari Executive Chairman

Mr. Ferrari is a founder, Director, and the Executive Chairman of Tenon Medical. Since 2000, he has been the Managing Director of Denovo Ventures, focusing on Medical Devices and Biotechnology. Mr. Ferrari previously served as CEO and Chairman of the Board of Directors of PQ Bypass, which was successfully acquired by Endologix. He has also held executive chairman roles at Medlumics, S.L., Heart Beam Inc., and Sentreheart (acquired by Atricure), and was a co-founder of TransAortic (acquired by Medtronic). Mr. Ferrari has been instrumental in raising over $1 billion for companies and has contributed to over $2 billion in acquisitions.

Richard Ginn Chief Technology Officer

Mr. Ginn is a founder of Tenon Medical, serving as its Chief Technology Officer and a Director. His work primarily focuses on intellectual property and product development, and he is a named inventor on over 300 patents for medical devices. Mr. Ginn has also played a role in raising more than $100 million in venture capital. In 2013, he founded TransAortic Medical, an embolic protection device company, where he holds the positions of President, CEO, and Director.

Wyatt Geist Chief Innovation Officer

Mr. Geist serves as the Chief Innovation Officer for Tenon Medical. His professional background includes expertise in Microbiology, Biochemistry, and Engineering.

The key risks to Tenon Medical (TNON) include its ongoing financial instability, intense market competition in the sacroiliac joint (SIJ) fusion sector, and significant reliance on a single product line coupled with regulatory and reimbursement challenges.

1. Financial Instability and Lack of Profitability

Tenon Medical has consistently reported net losses and faces significant financial challenges. The company's profitability metrics are concerning, with deeply negative operating and net margins. Analysts have noted that the company is currently unprofitable and is not forecast to become profitable in the near future, leading to continued cash burn. The Altman Z-Score, a measure of financial distress, indicates a potential risk of bankruptcy within the next two years. While the company has shown revenue growth, the struggle to achieve consistent profitability remains a dominant risk to its long-term viability and investor confidence.

2. Intense Market Competition and Low Market Penetration of Surgical Solutions

The sacroiliac joint fusion market is highly competitive, with other companies offering minimally invasive SIJ fixation products. Tenon Medical faces competition from both established players and various non-surgical treatment options for chronic lower back pain, including systemic oral medications and opioids. Historically, the penetration of surgical solutions for SIJ dysfunction has been relatively low, estimated at 5-7% of the total market. This limited market penetration for surgical interventions, combined with a competitive landscape, poses a challenge for Tenon Medical to significantly expand its market share and achieve substantial revenue growth.

3. Reliance on a Single Product Line and Regulatory/Reimbursement Challenges

Tenon Medical's business is heavily concentrated on its CATAMARAN SIJ Fusion System, with the majority of its revenue derived from sales of this single product to a limited number of clinicians. While the company has FDA clearance for its system, the medical device industry is subject to stringent and evolving regulatory requirements. Furthermore, securing adequate and consistent reimbursement from third-party payors for its procedures is an ongoing uphill battle. Any adverse changes in regulatory policies, delays in obtaining necessary approvals for product enhancements, or difficulties in securing favorable reimbursement rates could significantly impact the company's commercial success and ability to generate revenue.

The addressable market for Tenon Medical's main products, primarily the CATAMARAN SIJ Fusion System, is the sacroiliac (SI) joint fusion market.

Global Market:

The global sacroiliac joint fusion surgery market was valued at approximately USD 721.2 million in 2023 and is projected to reach USD 2.49 billion by 2030, growing at a compound annual growth rate (CAGR) of 19.8% from 2024 to 2030. Another estimate indicates the global market size was USD 293.80 million in 2023 and is expected to grow at a CAGR of 19.3% from 2024 to 2030, reaching USD 984.9 million by 2030. This market growth is driven by the increasing prevalence of chronic lower back pain associated with SI joint dysfunction, technological advancements, and the rising adoption of minimally invasive surgical techniques.

U.S. Market:

The U.S. sacroiliac joint fusion market was estimated at USD 0.45 billion in 2024 and is projected to reach USD 1.12 billion by 2034, demonstrating a CAGR of 9.2% from 2024 to 2034. North America, particularly the U.S., dominated the global market in 2023, accounting for 41.1% of the revenue share due to advanced healthcare infrastructure, the presence of key companies, and favorable reimbursement policies.

Tenon Medical (TNON) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

1. Increased Procedural Volumes for the CATAMARAN SIJ Fusion System: Tenon Medical has consistently reported significant year-over-year increases in surgical procedures utilizing its flagship CATAMARAN SIJ Fusion System. For instance, the first quarter of 2024 saw a 42% rise in surgical procedures using the system, while the fourth quarter of 2023 experienced a 312% increase compared to the prior year. This sustained growth in adoption and use of its primary product is a fundamental driver of revenue.

2. Expansion of Product Portfolio and Market Reach through SImmetry+ SI Joint Fusion System and Strategic Acquisitions: The company has broadened its product offerings through strategic actions such as the acquisition of sacroiliac joint-specific assets from SiVantage and the subsequent FDA clearance and commercialization of the SImmetry+ SI Joint Fusion System. This expansion allows Tenon Medical to address a wider range of sacro-pelvic fixation and fusion needs, thereby capturing a larger market share.

3. Expansion of Commercial Infrastructure and New Physician Adoption: Tenon Medical is actively investing in and restructuring its commercial infrastructure, including its sales force, and focusing on training and engaging new physician adopters for both the Catamaran and SImmetry+ systems. This strategic emphasis on deepening market penetration by increasing the number of trained surgeons and expanding its sales footprint is crucial for driving future sales.

4. Leveraging Positive Clinical Data and Regulatory Advancements: Favorable outcomes from post-market clinical studies, such as the MAINSAIL trial demonstrating an 83% fusion rate at 12 months with the Catamaran system, and ongoing FDA clearances, are vital for enhancing product credibility and increasing physician confidence. These advancements support broader product adoption and strengthen the company's competitive position in the sacroiliac joint market.

Share Repurchases

• Tenon Medical has not engaged in any share repurchase programs over the last 3-5 years.

Share Issuance

• Subsequent to December 31, 2023, Tenon Medical issued approximately $3.85 million of Series A Preferred Stock, which resulted in approximately $2.6 million in gross proceeds.
• In early March 2026, Tenon Medical announced the closing of a private placement of Senior Original Issue Discount Convertible Notes Offering for gross proceeds of $4.3 million.
• The number of shares outstanding increased by 1,031.03% in the year leading up to March 2026, with 11.11 million shares outstanding as of that time.

Inbound Investments

• In early 2024, the company received approximately $2.6 million in gross proceeds from the issuance of Series A Preferred Stock.
• Tenon Medical closed a private placement of Senior Original Issue Discount Convertible Notes Offering, generating gross proceeds of $4.3 million in early March 2026.

Capital Expenditures

• Over the last 12 months leading up to March 2026, Tenon Medical's capital expenditures totaled -$794,000.
• In Q3 2025, the company invested -$111,000 in capital expenditures for funding long-term assets and infrastructure.
• For the fiscal year 2024, capital expenditures were reported as $186,000.